Fig. 4.
Effects of body weight and ADA on the PK of benralizumab for patients with asthma. Closed circles represent CL in patients when ADA results were negative; open circles represent CL in patients when ADA results were positive. Red lines represent prediction curves [CL·(body weight/70)0.807], and blue lines represent locally weighted scatterplot smoothing (LOWESS). ADA antidrug antibodies, CL clearance, PK pharmacokinetics